Zacks Research Issues Pessimistic Estimate for ACAD Earnings

Key Points

• Zacks Research has lowered its earnings estimates for ACADIA Pharmaceuticals, predicting Q1 2026 EPS at $0.15, down from a previous estimate of $0.20.
• Despite the reduction, ACADIA Pharmaceuticals reported a strong quarterly performance, with actual EPS of $0.16 exceeding consensus estimates by $0.02 and revenues of $264.57 million.
• The consensus rating for ACADIA Pharmaceuticals stock is a "Moderate Buy", with the average price target set at $28.88.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Wednesday, August 27th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of $0.15 per share for the quarter, down from their prior estimate of $0.20. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.66 EPS, Q1 2027 earnings at $0.20 EPS, Q2 2027 earnings at $0.23 EPS and FY2027 earnings at $0.91 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $264.57 million during the quarter, compared to analysts' expectations of $263.07 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 earnings per share.

Several other equities research analysts have also recently commented on ACAD. JPMorgan Chase & Co. lifted their target price on ACADIA Pharmaceuticals from $30.00 to $34.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Robert W. Baird boosted their price objective on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Monday, May 19th. UBS Group upped their target price on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Citigroup reiterated an "outperform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, August 7th. Finally, Mizuho boosted their price target on shares of ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $28.88.

ACADIA Pharmaceuticals Trading Down 0.9%

Shares of NASDAQ ACAD opened at $25.99 on Monday. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $26.65. The company has a 50-day moving average of $23.35 and a two-hundred day moving average of $19.96. The company has a market cap of $4.38 billion, a PE ratio of 19.54, a P/E/G ratio of 6.62 and a beta of 0.75.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director Laura Brege sold 14,446 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the transaction, the director owned 15,095 shares of the company's stock, valued at $328,769.10. The trade was a 48.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark C. Schneyer sold 22,000 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $25.18, for a total value of $553,960.00. Following the sale, the executive vice president directly owned 40,130 shares in the company, valued at $1,010,473.40. The trade was a 35.41% decrease in their position. The disclosure for this sale can be found here. Company insiders own 28.30% of the company's stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals by 645.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 310,332 shares of the biopharmaceutical company's stock valued at $5,065,000 after buying an additional 268,714 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ACADIA Pharmaceuticals by 627.3% during the first quarter. GAMMA Investing LLC now owns 3,513 shares of the biopharmaceutical company's stock worth $58,000 after acquiring an additional 3,030 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $247,000. Amalgamated Bank lifted its holdings in shares of ACADIA Pharmaceuticals by 757.7% in the first quarter. Amalgamated Bank now owns 35,002 shares of the biopharmaceutical company's stock valued at $581,000 after purchasing an additional 30,921 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of ACADIA Pharmaceuticals by 28.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,086,840 shares of the biopharmaceutical company's stock worth $19,932,000 after buying an additional 243,082 shares in the last quarter. 96.71% of the stock is owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.